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In this issue of HPB, Sukharamwala et al.1 have performed a sys-
tematic review and meta-analysis of the literature with the aim of
analysing the efficacy of major pancreatic surgery among the
elderly population. The data were analysed in two ways by defin-
ing elderly as those over 75 years and a further subgroup of those
over 80 years of age. The search period ranged from 1990 to 2012.
Eleven studies were identified and included 5186 patients. The
primary endpoints were defined as peri-operative morbidity and
mortality. Secondary endpoints included specific complications
and length of hospital stay. Perhaps not surprisingly those who
were older were found to have a greater mortality but not overall
morbidity although those in older age groups did have a higher
risk of post-operative pneumonia. Of the 161 patients who were
>75 years, the overall morbidity was 54% and mortality 6.8%
compared with 57% and 1.5%, respectively, in the 461 patients
younger than 75 years. In those 333 patients over 80 years of age,
the mortality and morbidity was 3.6% and 53% compared with
1.8% and 41%, respectively, for those 4226 patients less than
80 years of age. Overall, there was no difference in hospital stay.
So how should these data be interpreted? These figures suggest
that a pancreaticoduodenectomy can be performed safely in an
elderly cohort of patients but should they be applied to the popu-
lation in general. First, it is highly likely that a significant selection
bias exists within these data. Those that have been operated on are
likely to represent the ‘cream of the crop’ of those elderly patients
presenting with peri-ampullary malignancy. In addition and
judging by the mortality rates in the younger cohort, it is highly
likely that these results have been published by high-volume
centres of excellence.2 Therefore, these data may not be able to be
extrapolated to the population in general.3,4
Perhaps what is most concerning are the endpoints that were
not included for analysis (presumably because they were not avail-
able from the data analysed). It is known that resectional surgery
alone for pancreatic adenocarcinoma offers little in terms of sur-
vival benefit over palliation.5 Therefore to get any meaningful
benefit from radical surgery, this needs to be combined with adju-
vant chemotherapy.6 Given the toxicity associated with adjuvant
chemotherapy7 any primary endpoint when looking at outcomes
for elderly patients after a pancreaticoduodenectomy should
include morbidity and mortality from chemotherapy. In addition,
it should be analysed on an intention-to-treat basis so that drop
out from treatment arms (surgery or chemotherapy) are identi-
fied. However, data on elderly patients undergoing chemotherapy
after a pancreaticoduodenectomy are hard to find. In the ESPAC-3
trial7, the 75th percentile for age was 69 years suggesting that few
patients in their 8th and 9th decade were actually enrolled.
One must also consider what the ultimate goal is for these
elderly patients. Is it 5-year survival figures or should outcome
actually represent the more holistic approach to the patient in
terms of quality of life. Two population-based studies3,4 have
shown that up to 27%–38% of patients over 80 years undergoing
a pancreatic resection are discharged to nursing care facilities
rather than directly home. Of those discharged home, 31%
required help within the home.3 In addition, the 5-year survival
figures (11%) are lower than that achieved for younger patients.4
The importance of informed consent for these patients should not
be underestimated. How many fully informed octogenarians,
when faced with a median survival of 9–12 months with palliation
and a minimal risk to their immediate quality of life, would rather
opt for a possible median survival of 10–14 months4 with radical
intervention which carries a 50% morbidity1 and a significant
chance of not returning home irrespective of whether it is fol-
lowed by 6 months of chemotherapy.
From a health economic perspective, Riall et al.3 have shown
that over the last decade the mortality in the elderly has fallen but
rates for transfer to nursing level care have increased. In times of
financial austerity, health care providers will have to face up to
these issues and ask ‘Is this the best use of a scarce health dollar?’
The current paper by Sukharamwala et al.1 highlights the
importance of good quality data from which to inform patients
about the right treatment for them as individuals. No doubt there
will be some physiologically fit octogenarians who will present
with neoplasms with a more favourable prognosis. On occasion, a
radical approach will be appropriate but for the majority what is
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technically possible may not necessarily be the best option. Given
the increasing prevalence of octogenarians with technically resec-
table peri-ampullary tumours studies measuring appropriate end
points are urgently needed.
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